Why Eli Lilly Stock is the ‘Nvidia’ of GLP-1 Meds
Investing in Eli Lilly now could mimic early Nvidia gains in AI. Learn why GLP-1 drugs are transforming healthcare investing.
- Latest
- Trending
Investing in Eli Lilly now could mimic early Nvidia gains in AI. Learn why GLP-1 drugs are transforming healthcare investing.
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Eli Lilly launches affordable Zepbound vials, easing supply issues and competing with Novo Nordisk's weight-loss drug.
Explore strategies to safeguard your investments during economic downturns with insights from experts like Matt Higgins.
Lilly's new Boston facility enhances RNA/DNA research, hosting 500 scientists and expanding Gateway Labs to the East Coast.
Discover how Novo Nordisk, Moderna, and Regeneron are poised for growth amidst market volatility with innovative biotech solutions.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.